HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Agnès Veyradier Selected Research

Thrombotic Thrombocytopenic Purpura

1/2022TTP: From empiricism for an enigmatic disease to targeted molecular therapies.
1/2022Identification of a novel genetic locus associated with immune-mediated thrombotic thrombocytopenic purpura.
11/2021Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP.
11/2021A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
8/2021Thrombotic Thrombocytopenic Purpura: When Basic Science Meets Clinical Research.
1/2021N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP.
1/2021Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
1/2021Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
1/2021Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment.
1/2021Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Agnès Veyradier Research Topics

Disease

72Thrombotic Thrombocytopenic Purpura
01/2022 - 04/2002
30Thrombotic Microangiopathies
05/2022 - 04/2002
11acquired Thrombotic thrombocytopenic purpura
11/2020 - 01/2012
10Thrombocytopenia (Thrombopenia)
01/2020 - 10/2004
9Neoplasms (Cancer)
12/2018 - 04/2002
8Hemolytic-Uremic Syndrome
05/2022 - 04/2002
8Hemolytic Anemia
01/2020 - 10/2004
6Autoimmune Diseases (Autoimmune Disease)
02/2021 - 12/2006
6Infections
05/2016 - 05/2002
5Hemorrhage
01/2021 - 03/2013
4Atypical Hemolytic Uremic Syndrome
05/2022 - 03/2003
4Thrombosis (Thrombus)
11/2020 - 01/2003
4von Willebrand Diseases (von Willebrand's Disease)
12/2019 - 11/2005
3Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome)
08/2021 - 10/2004
3Hemolysis
01/2021 - 04/2002
3Critical Illness (Critically Ill)
01/2021 - 01/2018
3Anemia
06/2019 - 04/2017
3Diarrhea
01/2018 - 05/2002
2Hypertension (High Blood Pressure)
05/2022 - 01/2021
2Inflammation (Inflammations)
01/2021 - 01/2018
2Pre-Eclampsia (Preeclampsia)
11/2020 - 07/2011
2Neurologic Manifestations (Neurological Manifestations)
01/2020 - 07/2004
2Cytopenia
12/2019 - 04/2017
2Venous Thrombosis (Deep-Vein Thrombosis)
01/2018 - 04/2014
2Ischemia
01/2017 - 01/2009
2Type 2 von Willebrand Disease
01/2016 - 11/2005
2Disseminated Intravascular Coagulation
10/2015 - 11/2013
2Sepsis (Septicemia)
11/2013 - 04/2007
2Connective Tissue Diseases (Connective Tissue Disease)
03/2012 - 05/2002
2HIV Infections (HIV Infection)
03/2012 - 07/2004
1Chronic Kidney Failure (Chronic Renal Failure)
11/2021
1Ischemic Stroke
08/2021
1Hemophilia A (Haemophilia)
02/2021
1Acute Kidney Injury (Acute Renal Failure)
01/2021
1Sickle Cell Anemia (Hemoglobin S Disease)
01/2021
1COVID-19
01/2021
1Eclampsia
11/2020
1Brain Diseases (Brain Disorder)
01/2020
1Paralysis (Palsy)
01/2020
1Seizures (Absence Seizure)
01/2020
1Delirium
12/2019
1Stroke (Strokes)
06/2019
1Purpura
11/2018
1Chronic Disease (Chronic Diseases)
10/2018

Drug/Important Bio-Agent (IBA)

47thiamine triphosphorate (TTP)IBA
01/2022 - 05/2002
20von Willebrand FactorIBA
11/2021 - 04/2002
17Metalloproteases (Metalloproteinases)IBA
01/2021 - 05/2002
14DisintegrinsIBA
01/2021 - 01/2009
14ThrombospondinsIBA
01/2021 - 01/2009
13Rituximab (Mabthera)FDA Link
01/2021 - 02/2004
12AutoantibodiesIBA
11/2021 - 03/2006
8ADAMTS13 ProteinIBA
01/2021 - 04/2002
6AntibodiesIBA
11/2020 - 07/2004
5Biological ProductsIBA
02/2021 - 08/2009
4Shiga Toxin (Shigella Toxin)IBA
05/2022 - 05/2002
4caplacizumabIBA
11/2021 - 11/2019
3Biomarkers (Surrogate Marker)IBA
01/2021 - 01/2020
3Hemostatics (Antihemorrhagics)IBA
01/2021 - 03/2009
3EnzymesIBA
11/2020 - 03/2009
3Pharmaceutical PreparationsIBA
11/2020 - 08/2006
3AntigensIBA
01/2020 - 07/2011
3Glycoproteins (Glycoprotein)IBA
12/2019 - 03/2016
3Immunoglobulin G (IgG)IBA
09/2019 - 05/2016
3AnticoagulantsIBA
06/2019 - 01/2018
3Fibrinogen (Factor I)FDA Link
01/2018 - 03/2009
2HLA Antigens (Human Leukocyte Antigens)IBA
01/2022 - 01/2018
2CreatinineIBA
11/2021 - 01/2018
2Complement System Proteins (Complement)IBA
11/2020 - 03/2009
2SteroidsIBA
01/2020 - 02/2014
2Hemoglobins (Hemoglobin)IBA
12/2019 - 01/2018
2Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
12/2018 - 03/2012
2Antinuclear AntibodiesIBA
04/2017 - 07/2004
2Dacarbazine (DIC)FDA LinkGeneric
10/2015 - 11/2013
2Interleukin-6 (Interleukin 6)IBA
11/2013 - 07/2011
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2012 - 02/2004
1Antiphospholipid AntibodiesIBA
08/2021
1Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA
08/2021
1Factor VIII (Coagulation Factor VIII)IBA
02/2021
1GemcitabineFDA Link
01/2021
1eculizumabFDA Link
01/2021
1EpitopesIBA
11/2020
1HLA-DRB1 Chains (HLA DRB1)IBA
10/2020
1Lenalidomide (CC 5013)FDA Link
01/2020
1TroponinIBA
12/2019
1SolventsIBA
12/2019
1amotosalenIBA
12/2019
1Detergents (Detergent)IBA
12/2019
1Anti-Idiotypic AntibodiesIBA
01/2019
1AntithrombinsIBA
01/2018

Therapy/Procedure

10Plasma Exchange
01/2020 - 10/2002
8Therapeutics
08/2021 - 03/2006
6Drug Therapy (Chemotherapy)
01/2021 - 04/2002
3Transplantation
04/2007 - 05/2002
2Renal Replacement Therapy (Therapies, Renal Replacement)
01/2021 - 01/2018
2Kidney Transplantation
01/2019 - 10/2002
2Salvage Therapy
08/2016 - 11/2012
2Organ Transplantation
05/2016 - 06/2006
2Central Venous Catheters
04/2014 - 01/2003
1Off-Label Use
01/2020
1Artificial Respiration (Mechanical Ventilation)
01/2020